|
Real-time Estimate
Cboe BZX
22:43:34 01/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 20.36 USD | -3.07% |
|
-9.60% | -34.68% |
| 08-14 | Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating | MT |
| 08-13 | Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 80.44M | - | - | - | ||
| 1,031B | |||||
| 638B | - | ||||
| 462B | |||||
| 359B | |||||
| 335B |
Select your edition
All financial news and data tailored to specific country editions
